CIK 0001615219 · Non-accelerated filer<br>Smaller reporting company
Decoy Therapeutics Inc.
Sign in to watch- Ticker
- DCOY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465087339
- Phone
- 346-772-0346
- Business address
- 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021
- Former names
- Salarius Pharmaceuticals, Inc., Flex Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-06 | McVicar William K. Director | Purchase | +26,553 | $0.19 | $5K | 26,553 |
| 2022-06-03 | HANISH ARNOLD C Director | Purchase | +28,000 | $0.18 | $5K | 46,350 |
| 2022-05-31 | Rosenblum Mark J Exec VP Finance, CFO | Purchase | +28,000 | $0.18 | $5K | 148,319 |
| 2022-05-26 | Arthur David J. Chief Executive Officer | Purchase | +3,400 | $0.18 | $612 | 263,074 |
| 2022-05-26 | Arthur David J. Chief Executive Officer | Purchase | +18,600 | $0.18 | $3K | 281,674 |
| 2022-05-26 | Arthur David J. Chief Executive Officer | Purchase | +708 | $0.18 | $127 | 282,382 |
| 2022-05-26 | Arthur David J. Chief Executive Officer | Purchase | +10,392 | $0.18 | $2K | 292,774 |
| 2022-05-26 | Arthur David J. Chief Executive Officer | Purchase | +10,800 | $0.18 | $2K | 303,574 |
| 2022-05-03 | Arthur David J. Chief Executive Officer | Grant or award | +10,000 | $0.19 | $2K | 259,674 |
| 2022-05-03 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award | +10,000 | $0.19 | $2K | 120,319 |
| 2022-03-03 | Rosenblum Mark J Exec VP Finance, CFO | Purchase | +76,246 | $0.39 | $30K | 110,319 |
| 2022-03-03 | Arthur David J. Chief Executive Officer | Purchase | +139,488 | $0.39 | $55K | 249,674 |
| 2022-01-20 | McCreedy Bruce J Jr. Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-20 | Lieber Jonathan I Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-20 | McVicar William K. Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-20 | Arthur David J. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2022-01-20 | Burleson Tess Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-20 | HANISH ARNOLD C Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-20 | Lammers Paul Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2022-01-20 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 |
Page 3 of 6 · 107 trades